ATE325117T1 - 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten - Google Patents
3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonistenInfo
- Publication number
- ATE325117T1 ATE325117T1 AT03715209T AT03715209T ATE325117T1 AT E325117 T1 ATE325117 T1 AT E325117T1 AT 03715209 T AT03715209 T AT 03715209T AT 03715209 T AT03715209 T AT 03715209T AT E325117 T1 ATE325117 T1 AT E325117T1
- Authority
- AT
- Austria
- Prior art keywords
- dihydrocinolin
- compounds
- receptor antagonists
- nr2b receptor
- nr2b
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37593902P | 2002-04-26 | 2002-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE325117T1 true ATE325117T1 (de) | 2006-06-15 |
Family
ID=29270728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03715209T ATE325117T1 (de) | 2002-04-26 | 2003-04-15 | 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten |
Country Status (15)
Country | Link |
---|---|
US (1) | US6713490B2 (de) |
EP (1) | EP1499606B8 (de) |
JP (1) | JP2005524696A (de) |
AR (1) | AR039663A1 (de) |
AT (1) | ATE325117T1 (de) |
AU (1) | AU2003219398A1 (de) |
BR (1) | BR0309778A (de) |
CA (1) | CA2483636A1 (de) |
DE (1) | DE60305026T2 (de) |
ES (1) | ES2258716T3 (de) |
MX (1) | MXPA04010549A (de) |
PA (1) | PA8572601A1 (de) |
TW (1) | TW200406402A (de) |
UY (1) | UY27776A1 (de) |
WO (1) | WO2003091241A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
CA2541162A1 (en) * | 2003-10-08 | 2005-04-21 | Pfizer Inc. | Fused lactam compounds |
ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
EP1736474A4 (de) * | 2004-04-07 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | Piperidinderivat |
HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
EP2116618A1 (de) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnose und Behandlung des Kawasaki-Syndroms |
WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
EP2437740B1 (de) * | 2009-03-31 | 2015-04-29 | Tinnitus Research Initiative (TRI) | Behandlung von tinnitus und relevanten funktionsstörungen des gehörs |
WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
WO2012042314A1 (en) | 2010-10-02 | 2012-04-05 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
ES2146578T3 (es) | 1990-05-10 | 2000-08-16 | Pfizer | Indolona neuroprotectora y derivados relacionados. |
DE69309297T2 (de) | 1992-10-30 | 1997-07-03 | Pfizer | Neuroprotektive 3,4-dihydro-2(1h)-chinolone |
PA8525601A1 (es) | 2000-08-21 | 2002-04-25 | Hoffmann La Roche | Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-15 EP EP03715209A patent/EP1499606B8/de not_active Expired - Lifetime
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en active IP Right Grant
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2483636A1 (en) | 2003-11-06 |
ES2258716T3 (es) | 2006-09-01 |
UY27776A1 (es) | 2003-11-28 |
WO2003091241A1 (en) | 2003-11-06 |
AU2003219398A1 (en) | 2003-11-10 |
EP1499606A1 (de) | 2005-01-26 |
EP1499606B8 (de) | 2006-08-30 |
MXPA04010549A (es) | 2005-02-17 |
DE60305026T2 (de) | 2006-10-12 |
JP2005524696A (ja) | 2005-08-18 |
EP1499606B1 (de) | 2006-05-03 |
DE60305026D1 (de) | 2006-06-08 |
US6713490B2 (en) | 2004-03-30 |
BR0309778A (pt) | 2005-03-08 |
PA8572601A1 (es) | 2004-12-16 |
US20030216430A1 (en) | 2003-11-20 |
TW200406402A (en) | 2004-05-01 |
AR039663A1 (es) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
ATE381565T1 (de) | 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten | |
ATE284214T1 (de) | Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten | |
ATE518834T1 (de) | 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten | |
ATE414074T1 (de) | 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl- piperidine als cgrp-antagonisten | |
SI1638969T1 (sl) | Antagonisti cgrp receptorjev | |
IL173512A0 (en) | Cyclopropyl derivatives as nk3 receptor antagonists | |
IL171930A0 (en) | Imidazole derivatives as glutamate receptor antagonists | |
ATE325117T1 (de) | 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten | |
ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
HK1058360A1 (en) | 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists. | |
DE60133931D1 (de) | Kondensierte purinderivate als a1-adenosinrezeptorantagonisten | |
DE60333866D1 (de) | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten | |
DE60325613D1 (de) | 5-Ä((2,3-difluorophenyl)methyl)thioÜ-7-äÄ(1S,2S)-2-hydroxy-1-(hydroxymethyl)propylÜaminoüthiazoloÄ4,5-dÜpyrimidin-2(3H)-on als CXCR2 Antagonist | |
DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
IS8278A (is) | Sýkóprópýl afleiður sem NK3 viðtaka mótlyf | |
ATE338043T1 (de) | 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten | |
ATE401333T1 (de) | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors | |
AP2005003196A0 (en) | Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor. | |
PL375263A1 (en) | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists | |
ATE519750T1 (de) | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3- benzodiazepin-2(1h)-on | |
EP1809296A4 (de) | Neue [1,4]-benzodiazepine als vasopressin v2-rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |